Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.
Alberto Cordero-FortMª Rosa Fernández OlmoGustavo A Cortez QuirogaCesar Romero-MenorLorenzo FácilaJosé Seijas-AmigoJuan Rondán MurilloMiriam SandinMoisés Rodríguez-MañeroMaría C Bello MoraAlfonso ValleAisa FornoviRoman Freixa PamiasJordi BañerasPedro Blanch GarcíaMaría Milagros Clemente LorenzoSergio Sánchez-ÁlvarezLuis López-RodríguezJosé R González-JuanateyPublished in: European journal of clinical investigation (2022)
This multicenter and retrospective registry of real-world patients treated with PCSK9 inhibitors demonstrates a positive effect on cholesterol remnants and lipid residual risk beyond LDLc reductions.
Keyphrases